eFFECTOR Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Excellent. So good morning, everyone. Welcome to the JMP Securities healthcare conference. It's my pleasure to welcome all of you and to welcome our first presenting company, eFFECTOR Therapeutics. Presenting for the company is Steve Worland, President and CEO.
And just so you guys know, eFFECTOR is a developer of Selective Translation Regulator Inhibitors, which is a mouthful, but it is a new class of, I want to say, compounds and development that not too many people are doing. So here to tell us about the story is Steve.
Great. Thank you very much, [Ryan]. And thank you for the opportunity to present today.
So we really view eFFECTOR Therapeutics as developing a next generation of targeted therapeutics. We're going after pathways that are well recognized, but a different point of intervention and a different outcome to block tumor cell growth and ultimately to reduce tumor burden in patients.
So everybody's familiar with the RAS and the PI3K pathways.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
